Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany

Objective To identify sick leave days (SLD) predictors after starting antidepressant (AD) treatment in patients affected by major depressive disorder (MDD), managed by general practitioners, with a focus on different AD therapeutic approaches. Methods Retrospective study on German IQVIA(R) Disease A...

Descripción completa

Detalles Bibliográficos
Autores: Kasper, Siegfried, Bonelli, Annalisa, Cattaneo, Agnese, Comandini, Alessandro, Di Dato, Giorgio, Heiman, Franca, Pegoraro, Valeria, Palao, Diego, Roca, Miquel, Volz, Hans-Peter
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Conselleria de Salut i Consum del Govern de les Illes Balears
Repositorio:Docusalut
Idioma:inglés
OAI Identifier:oai:docusalut.com:20.500.13003/19762
Acceso en línea:https://hdl.handle.net/20.500.13003/19762
Access Level:acceso abierto
Palabra clave:Sick Leave
General Practice
Depressive Disorder, Major
Young Adult
Adult
Germany
Antidepressive Agents
Humans
Middle Aged
Retrospective Studies
Antidepresivos
Trastorno Depresivo Mayor
Humanos
Persona de Mediana Edad
Adulto Joven
Ausencia por Enfermedad
Alemania
Estudios Retrospectivos
Adulto
Medicina General
Major depressive disorder
sick leave
antidepressants
therapeutic approach
real world evidence
Descripción
Sumario:Objective To identify sick leave days (SLD) predictors after starting antidepressant (AD) treatment in patients affected by major depressive disorder (MDD), managed by general practitioners, with a focus on different AD therapeutic approaches. Methods Retrospective study on German IQVIA(R) Disease Analyser database. 19-64 year old MDD patients initiating AD treatment between July-2016 and June-2018 were grouped by therapeutic approach (AD monotherapy versus combination/switch/add-on). Data were analysed descriptively by AD therapeutic approach, while a zero-inflated Poisson (ZIP) multiple regression model was run to evaluate SLD predictors. Results 8,891 patients met inclusion criteria (monotherapy: 66%; combination/switch/add-on: 34%). All covariates had an influence on SLD after AD treatment initiation. Focussing on variables that physicians may more easily intervene to improve outcomes, it was found that the expected SLD number of combination/switch/add-on patients was 1.6 times that of monotherapy patients, and the expected SLD number of patients diagnosed with MDD before the decision to start AD treatment was 1.2 times that of patients not diagnosed with MDD. Conclusions A patient tailored approach in the selection of AD treatment at the time of MDD diagnosis may improve functional recovery and help to reduce the socio-economic burden of the disease.

Similares en LA Referencia